Kidney patients needed for drug dosing study

NCT ID NCT06845813

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how different levels of kidney function affect the way the body processes a single dose of the drug AZD6234. Researchers compared 24 adults with various degrees of kidney impairment to healthy volunteers. The goal was to understand how the drug moves through the body and whether it is safe, which will help guide future dosing recommendations for people with kidney disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD6234
What this could lead to: If successful, this study could help doctors determine the right dose of AZD6234 for people with kidney problems, making the drug safer and more effective for them.
What could go wrong: This is a very early (Phase 1) study with only 24 participants, so results may not apply to everyone. The drug's safety and effectiveness for treating any condition are not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL IMPAIRMENT

Contacts and locations

Locations

Research Site

Lake Forest, California, 92630, United States
Research Site

Orlando, Florida, 32808, United States
Research Site

Orlando, Florida, 32809, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.